Señales en vivo de MDWD | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 may 2024 @ 16:00):

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration...

Stats
Volumen de hoy	40 513.00
Volumen promedio	78 048.00
Capitalización de mercado	177.02M
EPS	$0 ( 2024-03-21 )
Próxima fecha de ganancias	( $-0.400 ) 2024-06-04
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-24.87
ATR14	$0.0820 (0.44%)

Volumen Correlación

Largo: 0.01 (neutral)

Corto: 0.77 (moderate)

Signal:(47.727) Neutral

Mediwound Ltd Correlación

10 Correlaciones Más Positivas
TBSAU	0.936
ENTF	0.935
TCOM	0.928
VPCB	0.926
FNVT	0.925
CCLP	0.925
LEGA	0.924
AGGR	0.924
FRONU	0.922
AFAR	0.921

10 Correlaciones Más Negativas
GPRO	-0.922
OLPX	-0.921
TLGT	-0.92
GOODM	-0.918
CNTG	-0.914
UDMY	-0.911
AGRX	-0.909
BHTG	-0.906
PTE	-0.905
PACB	-0.904

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Mediwound Ltd Correlación - Moneda/Commodity

-0.31
( neutral )

-0.41
( neutral )

0.00
( neutral )

-0.07
( neutral )

0.41
( neutral )

0.47
( neutral )

Mediwound Ltd Finanzas

Annual	2023
Ingresos:	$18.69M
Beneficio Bruto:	$2.95M (15.77 %)
EPS:	$-0.750

FY	2023
Ingresos:	$18.69M
Beneficio Bruto:	$2.95M (15.77 %)
EPS:	$-0.750

FY	2022
Ingresos:	$26.50M
Beneficio Bruto:	$13.17M (49.69 %)
EPS:	$-3.93

FY	2021
Ingresos:	$23.76M
Beneficio Bruto:	$8.77M (36.91 %)
EPS:	$-0.0711

Financial Reports:

No articles found.

Mediwound Ltd

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.